P
Polaryx Therapeutics Inc D
D
PLYX
1.93000
USD
-0.02
(-0.77%)
Market Closed
Volume
2,597
EPS
-0
Div Yield
-
P/E
-14
Market Cap
96,202,766
Title: Polaryx Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.